Sysmex America announced it will add the CellaVision® DC-1 to its portfolio of CellaVision products for low-volume hematology labs. The product received the Food and Drug Administration's 510(k) clearance on October 16, 2020. Now available in the United States and Canada, the CellaVision® DC-1 automates the process of performing blood cell differentials in low volume labs.
"The solution for both standalone and networked installation, the CellaVision DC-1 closes the technology gap between larger and smaller labs," said Andy Hay, chief operating officer of Sysmex America. "The CellaVision DC-1 provides labs high quality digital imaging for improved efficiency, quality, connectivity and staff proficiency."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
The CellaVision DC-1 eliminates the majority of manual steps traditionally done by lab technicians performing blood cell differentials for maximum speed and productivity. It's more standardized testing process helps reduce the negative impact of subjective interpretations and assessments.
"Enabling smaller labs across the globe to benefit from the same set of well-documented operational and clinical implementation benefits that we have provided larger labs has been a high priority for us," said Zlatko Rihter, president and CEO of CellaVision. "We are pleased to expand our long-standing partnership with Sysmex America as they bring the CellaVision DC-1 to the US market."